Compare Adaptive Biotechnologies Corp (ADPT) vs Applied Materials, Inc. (AMAT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Applied Materials, Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $19.94 (market cap $3.33B), while Applied Materials, Inc. trades at $573.54 (market cap $440.25B). The key difference: Applied Materials, Inc. is far larger — about 132.2× Adaptive Biotechnologies Corp's market cap, and Applied Materials, Inc. pays a 0.38% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | AMAT | |
|---|---|---|
Market Cap | $3.33B | $440.25B |
Sector | Health | Technology |
52-Week High | $22.37 | $723.00 |
52-Week Low | $10.24 | $156.25 |
Enterprise Value | $3.19B | $439.28B |
Dividend Yield | — | 0.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Applied Materials (AMAT) trades at $592.79, down 1.78% on the day, amid a broader bullish technical trend. The stock has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.86 surpassing the $2.68 estimate. Strong profitability is evident with a net income margin of 29.31% and ROE of 39.69%. Recent news highlights the company's positioning in the AI-driven semiconductor equipment boom, with the CEO calling it 'the greatest time in the history of our industry' (CNBC, 2026-05-28).
The outlook remains positive, supported by robust analyst sentiment (76.92% buy ratings) and a consensus price target of $622.57, offering potential upside. Key risks include high valuation multiples (P/E of 55.77) and dependence on sustained semiconductor capital expenditure cycles. The stock presents an opportunity for growth investors aligned with the AI infrastructure theme, but requires monitoring of execution and market cyclicality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Applied Materials, Inc.
Applied Materials is the world's largest supplier of semiconductor manufacturing equipment, providing materials engineering solutions to help make nearly every chip in the world. The firm's systems are used in nearly every major process step with the exception of lithography. Key tools include those for chemical and physical vapor deposition, etching, chemical mechanical polishing, wafer- and reticle-inspection, critical dimension measurement, and defect-inspection scanning electron microscopes.
Read more on AMAT →
